PROCEPT BioRobotics Co. (NASDAQ:PRCT) Shares Purchased by William Blair Investment Management LLC

William Blair Investment Management LLC raised its holdings in shares of PROCEPT BioRobotics Co. (NASDAQ:PRCT) by 12.6% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 239,285 shares of the company’s stock after acquiring an additional 26,783 shares during the period. William Blair Investment Management LLC’s holdings in PROCEPT BioRobotics were worth $19,267,000 as of its most recent SEC filing.

A number of other institutional investors also recently added to or reduced their stakes in PRCT. Raleigh Capital Management Inc. acquired a new stake in shares of PROCEPT BioRobotics in the 4th quarter worth approximately $32,000. Signaturefd LLC increased its position in shares of PROCEPT BioRobotics by 26.7% in the fourth quarter. Signaturefd LLC now owns 689 shares of the company’s stock worth $55,000 after acquiring an additional 145 shares in the last quarter. IFP Advisors Inc acquired a new stake in shares of PROCEPT BioRobotics during the fourth quarter valued at approximately $58,000. Arcadia Investment Management Corp MI purchased a new stake in shares of PROCEPT BioRobotics in the 4th quarter valued at approximately $64,000. Finally, Wilmington Savings Fund Society FSB acquired a new position in PROCEPT BioRobotics in the 3rd quarter worth approximately $64,000. Institutional investors and hedge funds own 89.46% of the company’s stock.

PROCEPT BioRobotics Stock Up 1.4 %

NASDAQ:PRCT opened at $57.80 on Thursday. PROCEPT BioRobotics Co. has a 1 year low of $45.56 and a 1 year high of $103.81. The stock has a 50-day moving average price of $68.87 and a two-hundred day moving average price of $78.75. The stock has a market cap of $3.17 billion, a price-to-earnings ratio of -29.64 and a beta of 1.05. The company has a current ratio of 6.02, a quick ratio of 5.07 and a debt-to-equity ratio of 0.21.

PROCEPT BioRobotics (NASDAQ:PRCT) last announced its earnings results on Tuesday, February 25th. The company reported ($0.35) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.34) by ($0.01). The company had revenue of $68.24 million during the quarter, compared to analyst estimates of $66.79 million. PROCEPT BioRobotics had a negative return on equity of 38.57% and a negative net margin of 50.07%. As a group, equities analysts expect that PROCEPT BioRobotics Co. will post -1.75 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several research analysts have weighed in on the stock. Truist Financial reiterated a “buy” rating and issued a $90.00 price objective (down previously from $105.00) on shares of PROCEPT BioRobotics in a research note on Wednesday, February 26th. Morgan Stanley decreased their target price on PROCEPT BioRobotics from $105.00 to $95.00 and set an “overweight” rating on the stock in a research report on Wednesday, February 26th. Finally, Wells Fargo & Company restated an “overweight” rating and set a $112.00 target price on shares of PROCEPT BioRobotics in a research report on Tuesday, December 3rd. One equities research analyst has rated the stock with a hold rating and six have issued a buy rating to the stock. Based on data from MarketBeat.com, PROCEPT BioRobotics presently has a consensus rating of “Moderate Buy” and a consensus target price of $94.29.

Insider Activity at PROCEPT BioRobotics

In other PROCEPT BioRobotics news, CFO Kevin Waters sold 733 shares of the business’s stock in a transaction that occurred on Tuesday, March 18th. The shares were sold at an average price of $57.06, for a total transaction of $41,824.98. Following the completion of the transaction, the chief financial officer now directly owns 107,991 shares in the company, valued at $6,161,966.46. The trade was a 0.67 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CEO Reza Zadno sold 5,475 shares of the company’s stock in a transaction on Tuesday, March 18th. The stock was sold at an average price of $57.06, for a total value of $312,403.50. Following the sale, the chief executive officer now owns 173,070 shares of the company’s stock, valued at approximately $9,875,374.20. This represents a 3.07 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 6,455 shares of company stock worth $368,322. Insiders own 17.40% of the company’s stock.

PROCEPT BioRobotics Company Profile

PROCEPT BioRobotics Corporation, a surgical robotics company, focuses on developing transformative solutions in urology in the United States and internationally. The company develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH).